Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Impinj Inc (PI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Impinj Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Impinj Inc trades at $140.86 (market cap $4.39B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.1× Impinj Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PI | |
|---|---|---|
Market Cap | $39.89B | $4.39B |
Sector | Health | Technology |
52-Week High | $491.22 | $241.91 |
52-Week Low | $278.09 | $91.34 |
Enterprise Value | $38.15B | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Impinj (PI) trades at $144.03, down 0.26% today, with a bullish technical signal supported by moving averages and a golden cross pattern. The company reported Q1 2026 earnings of $0.14 per share, beating estimates, but faces negative net income margins and high valuation multiples. Recent news highlights insider selling and upcoming Q2 2026 results, while analyst consensus remains strongly bullish with a $167.50 price target.
The outlook for PI is mixed: strong analyst support and technical momentum suggest upside potential, but profitability challenges and high valuations pose risks. Investment opportunity hinges on execution improving margins and revenue growth, while key risks include competitive pressures and insider selling trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
